Loading...
Market
What will Eisai and Biogen's next strategic move be after the CHMP decision by December 31, 2024?
2
Resolution / Starting Odds
File an appeal • 25%
Submit new data • 25%
Withdraw application • 25%
Other • 25%
Official announcements from Eisai or Biogen
Story
CHMP Recommends EU Rejection of Eisai and Biogen's Alzheimer's Drug Leqembi
Jul 26, 2024, 11:19 AM
On July 26, 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on lecanemab, also known as Leqembi, an Alzheimer's therapy developed by Eisai and Biogen, recommending its rejection in the European Union. This decision diverges from the stance of U.S. regulators, who have approved the medicine. The rejection is a significant setback for Eisai and Biogen, who were seeking to expand sales of the drug in Europe.
View original story
Similar markets
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%
Announce a new drug development • 25%
Seek partnerships or mergers • 25%
Focus on non-Alzheimer's projects • 25%
Other strategic move • 25%
Launches new product • 25%
Announces partnership • 25%
Pursues merger/acquisition • 25%
No major move • 25%
Approved • 25%
Conditional Approval • 25%
Not Approved • 25%
Approval Pending • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Approval • 33%
Conditional Approval • 33%
Rejection • 34%